Medison Pharma and Partners Healthcare could be in line for exits after the haematological and musculoskeletal disorder therapy developer filed to raise $86.3m.

US-based musculoskeletal disorder drug developer Keros Therapeutics filed for an $86.3m initial public offering on Monday that could enable healthcare network Partners Healthcare and pharmaceutical services provider firm Medison Pharma to exit. Keros is working on therapeutics that will target the Transforming Growth Factor-Beta protein to treat musculoskeletal and haematological disorders with a high unmet…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.